In a significant milestone for the treatment of obstructive sleep apnea (OSA), medical technology innovator Nyxoah has announced the successful implantation of the first patient in its BREATHE study. This landmark US post-approval clinical trial is designed to evaluate the long-term safety and real-world effectiveness of the Genio system, a pioneering bilateral hypoglossal nerve stimulation (HGNS) therapy. As the landscape of sleep medicine shifts toward more personalized, minimally invasive neurostimulation solutions, the BREATHE study stands as a critical endeavor to validate how this technology performs outside of the controlled environment of a pivotal clinical trial.
The procedure, which marks the official commencement of the study, was performed by Dr. Rolando Molina, an otolaryngologist at South Florida ENT Associates. The trial is being led by site principal investigator Dr. Edward Mezerhane, a sleep medicine physician at the PharmaDev Clinical Research Institute.
Main Facts: The Scope of the BREATHE Study
The BREATHE study is a multicenter, prospective, single-arm post-approval trial aimed at gathering comprehensive, long-term data on the Genio system. The study design is robust, with a recruitment target of up to 229 patients across as many as 25 clinical centers throughout the United States.
The core objective is to move beyond the initial data used for FDA approval, providing a window into how the Genio system operates in routine, daily clinical practice. By involving a diverse array of sites and practitioners, the study aims to capture a broad spectrum of patient experiences and clinical outcomes.
Primary Endpoints
The study focuses on two co-primary effectiveness endpoints, both measured at the 12-month mark:
- Apnea-Hypopnea Index (AHI): A key metric used to indicate the severity of sleep apnea by measuring the number of apnea and hypopnea events per hour of sleep.
- Oxygen Desaturation Index (ODI): A measurement that tracks how often a patient’s blood oxygen levels drop below a certain threshold during sleep.
Beyond effectiveness, the safety profile of the system is a primary focus. Researchers will be monitoring for device-related and procedure-related serious adverse events at the 12-month milestone and continuing with annual assessments for up to five years post-implantation.
Chronology: From Innovation to Clinical Implementation
The journey of the Genio system from conceptual design to its current position in the US market reflects the rapid evolution of neurostimulation technology.
- 2019: The Genio system receives the European CE Mark, establishing its safety and efficacy profile in European clinical settings and providing a foundation for international adoption.
- August 2025: The US Food and Drug Administration (FDA) grants approval for the Genio system, identifying it as a prescription-only device for a specific subset of OSA patients. This approval was a watershed moment for Nyxoah, validating the unique leadless, battery-free design of the system.
- September 2026: Nyxoah announces the successful first implant in the BREATHE post-approval study, signifying the transition from initial market entry to large-scale, long-term clinical data collection.
This timeline underscores a methodical approach to medical device deployment—moving from foundational research to regulatory approval, and now, to the rigorous, multi-year observation required to confirm long-term clinical utility.
Supporting Data: Why Bilateral Stimulation Matters
The Genio system represents a technological departure from traditional sleep apnea treatments. Unlike conventional therapies, which often rely on continuous positive airway pressure (CPAP) machines that can be cumbersome for patients to manage, or unilateral nerve stimulators, the Genio system offers a bilateral approach.
The Mechanism of Action
The system utilizes a patient-centered, leadless, and battery-free design. By stimulating both sides of the hypoglossal nerve, the Genio system facilitates a more coordinated and effective protrusion of the tongue. This bilateral stimulation is designed to prevent airway collapse more consistently than single-side stimulation, addressing the structural complexities of the upper airway that contribute to moderate to severe OSA.
The Need for Real-World Evidence
While pivotal clinical trials are essential for securing regulatory approval, they often feature highly controlled environments and carefully screened patient populations. The BREATHE study is designed to bridge the gap between "idealized" trial conditions and the "messiness" of real-world medicine. By documenting performance across 25 different centers, Nyxoah intends to prove that the therapy is not only effective in the hands of elite researchers but also consistently reliable when implemented by various sleep surgeons and ENT specialists across the country.
Official Responses and Clinical Perspectives
The initiation of the BREATHE study has drawn positive reactions from the medical community, highlighting the collaborative spirit between sleep medicine physicians and surgeons.
Dr. Rolando Molina, who performed the first implant, emphasized the transformative potential of the technology. "As an otolaryngologist dedicated to the treatment of sleep-disordered breathing, I have seen firsthand the significant impact obstructive sleep apnea has on patients’ health and quality of life," Molina stated. "The BREATHE study represents an exciting milestone in the evolution of sleep surgery and neurostimulation therapy. By performing the first implant in this study, we have the opportunity to help shape the future of sleep apnea treatment while offering eligible patients access to an additional therapeutic approach."
Dr. Edward Mezerhane, serving as the site principal investigator, echoed the sentiment, noting the ongoing struggle patients face with existing modalities. "Obstructive sleep apnea affects millions of people, yet many patients continue to struggle despite available therapies. The launch of the BREATHE study marks an exciting step forward in the evolution of sleep medicine, allowing us to evaluate an innovative bilateral hypoglossal nerve stimulation therapy in a real-world setting."
Olivier Taelman, CEO of Nyxoah, highlighted the strategic importance of the trial for the company’s broader mission. "The first BREATHE implant marks the start of the largest prospective study of Genio to date and the next step in building the long-term, real-world evidence base for bilateral hypoglossal nerve stimulation in the United States," Taelman said. "As adoption of Genio accelerates across US centers, BREATHE will document how the therapy performs in everyday practice, in the hands of both sleep physicians and surgeons, over five years. This is the evidence that patients, physicians, and payors expect."
Implications: The Future of OSA Treatment
The BREATHE study carries significant weight for several stakeholders: patients, clinicians, and health insurance providers.
Impact on Patient Care
For the millions of Americans suffering from moderate to severe OSA, the primary barrier to treatment is often the intolerance of CPAP therapy. If the BREATHE study confirms that the Genio system offers a durable, safe, and effective alternative over a five-year period, it could shift the standard of care. Patients who previously felt forced to choose between ineffective therapy and high-burden devices may find a more sustainable, "set-it-and-forget-it" solution.
Impact on Clinical Practice
The collaborative nature of the study—involving both sleep physicians who manage the diagnosis and titration, and surgeons who perform the implantation—reflects a multidisciplinary approach that is becoming increasingly common in high-level sleep medicine. The study will provide standardized protocols for how these specialists work together, potentially streamlining the patient journey from referral to successful implantation.
Impact on Payor Coverage
One of the most critical aspects of the BREATHE study is its role in "payor relations." Insurance companies and healthcare systems require longitudinal data to justify the long-term cost-effectiveness of new technologies. By documenting five-year outcomes, Nyxoah is proactively building the data set required to ensure that the Genio system remains an accessible, covered, and viable therapeutic option for a broad patient base.
Conclusion
As the BREATHE study progresses over the next half-decade, it will likely serve as a benchmark for how the medical industry approaches the post-market evaluation of neurostimulation therapies. The combination of its ambitious scope, the focus on long-term safety, and the commitment to real-world performance tracking signals a maturation in the treatment of obstructive sleep apnea.
For the healthcare community, the data generated by BREATHE will provide the clarity needed to refine treatment algorithms and improve patient selection. For Nyxoah, it represents a commitment to transparency and clinical rigor. Ultimately, the study is a testament to the fact that while technology can provide the tools, it is the long-term, real-world experience of the patient that truly defines the success of a medical innovation. As the study moves forward, the medical world will be watching closely, waiting to see how this leadless, bilateral approach redefines the standard of care for one of the most common and debilitating sleep disorders of the modern era.
